radly Friday, 03/13/20 10:32:07 PM Re: None Post # of 51 PharmaMar reports positive results for Aplidin® against coronavirus HCoV-229E These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC). PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19. Madrid, March 13th, 2020. PharmaMar (MSE:PHM) reports that the in vitro studies results of Aplidin® (plitidepsin) on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to Covid-19, have been positive with a potency of the nanomolar order. These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC) by Dr Luis Enjuanes, Dr Isabel Solá and Dr Sonia Zúñiga. These results confirm the hypothesis that the therapeutic target of Aplidin® (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus. With these data, PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.